慢性阻塞性肺疾病伴认知功能障碍患者血清lipocalin-2表达及意义

doi:10.3877/cma.j.issn.1674-6902.2022.01.007

目的

分析血清脂质运载蛋白-2(lipocalin-2)在慢性阻塞性肺疾病(chronic obstructive pulmonary disease, COPD)稳定期伴认知障碍患者血清中的表达变化及其意义。

方法

依据蒙特利尔认知评估量表(Montreal cognitive assessment, MoCA)评分，MoCA分值<26分者为认知受损，将43例COPD稳定期的患者分为认知障碍组23例及认知正常组20例，并选取20例健康体检者做对照组；采用酶联免疫吸附实验(ELISA)分别检测患者外周静脉血清脂质运载蛋白-2(lipocalin-2)水平；分析血清脂质运载蛋白-2与认知功能的相关性，根据血清lipocalin-2水平预测认知障碍的受试者工作特征(ROC)曲线。

结果

与健康对照组相比(60.37±10.77)μg/ml，COPD稳定期伴认知障碍患者血清lipocalin-2水平(82.76±12.90)μg/ml显著增加(P<0.05)；与COPD稳定期认知正常组(69.70±11.51)μg/ml相比，认知功能障碍组血清lipocalin-2水平显著升高，差别有统计学意义(P<0.05)。Pearson相关分析结果显示血清lipocalin-2水平与MoCA评分呈负相关(r＝-0.749，P<0.001)；血清lipocalin-2水平预测COPD稳定期患者认知功能障碍的ROC曲线下面积分别为0.804(95%CI 0.664~0.945，P<0.001)。

结论

血清lipocalin-2表达水平与COPD稳定期患者认知功能障碍密切相关。血清lipocalin-2水平检测可能成为COPD患者出现认知功能障碍的一个重要诊断指标。

关键词: 肺疾病，慢性阻塞性, 认知功能, 蒙特利尔认知评估量表, 脂质运载蛋白-2

Objective

To investigate the correlation and clinical significance of serum lipocalin-2 level with cognitive impairment in patients with the stable stage of chronic obstructive pulmonary disease (COPD).

Methods

According to the Montreal cognitive assessment(MoCA)scale standard for evaluation, a cutoff score of <26 defined as mild cognitive impairment(MCI). A total of 43 patients in the stable stage of COPD were divided into a cognitive impairment group(Cog I) (23 patients)and a cognitive normal group (Cog N)(20 patients), and 20 healthy Subjects as control group. The level of serum lipocalin-2 in each group was detected by enzyme-linked immunosorbent assay (ELISA), the correlation between lipocalin-2 and cognitive function was analyzed, and the ROC curve of cognitive impairment was predicted according to the level of lipocalin-2.

Results

Compared with the healthy control group(60.37±10.77)μg/ml, the serum level of lipocalin-2 in stable COPD patients with cognitive impairment (82.76±12.90) μg/ml was significant higher(P<0.05). Compared with than the cognitive normal group (69.70±11.51)μg/ml, the protein level of lipocalin-2 was increased in serum of stable COPD patients with cognitive impairment(P<0.05). Pearson line correlation revealed that the serum level of lipocalin-2 was negatively correlated with MoCA score (r=-0.749, P<0.001), The areas under ROC curve of serum lipocalin-2 level to predict cognitive dysfunction in the COPD patients was 0.804 (95%CI 0.664-0.945, P<0.001).

Conclusion

The serum lipocalin-2 level is closely related to the cognitive dysfunction of stable COPD patients. The detection of serum lipocalin-2 level may be an important diagnostic index of cognitive dysfunction in COPD patients.

Key words: Chronic obstructive pulmonary disease, Cognitive function, Montreal cognitive assessment, lipocalin-2

图1 三组人群血清lipocalin-2浓度；注：*与对照组相比，P<0.05，#与认知正常组(Cog N)相比，P<0.05

表1 三组人群MoCA评分比较

变　量	对照组(n＝20)	认知正常组(n＝20)	认知障碍组(n＝23)
视空间/执行(5)	4.75±0.55	4.65±0.58	3.04±1.07^ab
命名(3)	2.65±0.49	2.50±0.51	2.39±0.58^a
注意(6)	5.35±0.49	5.40±0.50	3.13±0.69^ab
语言(3)	2.70±0.57	2.60±0.60	2.57±0.59^a
抽象(2)	1.85±0.37	1.90±0.31	1.48±0.51^ab
延时回忆(5)	4.25±0.79	4.15±0.75	2.39±1.11^ab
定向(6)	5.85±0.37	5.75±0.72	4.74±1.14^ab
总分(30)	27.40±1.19	26.95±1.05	19.74±2.96^ab

表1 三组人群MoCA评分比较

变　量	对照组(n＝20)	认知正常组(n＝20)	认知障碍组(n＝23)
视空间/执行(5)	4.75±0.55	4.65±0.58	3.04±1.07^ab
命名(3)	2.65±0.49	2.50±0.51	2.39±0.58^a
注意(6)	5.35±0.49	5.40±0.50	3.13±0.69^ab
语言(3)	2.70±0.57	2.60±0.60	2.57±0.59^a
抽象(2)	1.85±0.37	1.90±0.31	1.48±0.51^ab
延时回忆(5)	4.25±0.79	4.15±0.75	2.39±1.11^ab
定向(6)	5.85±0.37	5.75±0.72	4.74±1.14^ab
总分(30)	27.40±1.19	26.95±1.05	19.74±2.96^ab

1	任成山，王关嵩，钱桂生. 慢性阻塞性肺疾病的成因及其治疗的困惑与希望[J/CD]. 中华肺部疾病杂志(电子版), 2019, 12(2): 127-141.
2	Wang Y, Jia M, Yan X, et al. Increased neutrophil gelatinase-associated lipocalin (NGAL) promotes airway remodelling in chronic obstructive pulmonary disease[J]. Clin Sci (Lond), 2017, 131(11): 1147-1159.
3	Ferreira AC, Da Mesquita S, Sousa JC, et al. From the periphery to the brain: lipocalin-2, a friend or foe？[J]. Prog Neurobiol, 2015, 131: 120-136.
4	Pinyopornpanish K, Chattipakorn N, Chattipakorn SC. Lipocalin-2: Its perspectives in brain pathology and possible roles in cognition[J]. J Neuroendocrinol, 2019, 31(10): e12779.
5	中华医学会呼吸病学分会慢性阻塞性肺疾病学组. 慢性阻塞性肺疾病诊治指南[J]. 中华结核和呼吸杂志，2013, 36(4): 255-264.
6	Huang Kewu, Yang Ting, Xu Jianying, et al. Prevalence, risk factors, and management of asthma in China: a national cross-sectional study[J] . Lancet, 2019, 394: 407-418.
7	Villeneuve S, Pepin V, Rahayel S, et al. Mild cognitive impairment in moderate to severe COPD: a preliminary study[J]. Chest, 2012, 142(6): 1516-1523.
8	Kakkera Krishna, Padala Kalpana P, Kodali Maneetha, et al. Association of chronic obstructive pulmonary disease with mild cognitive impairment and dementia[J] . Curr Opin Pulm Med, 2018, 24: 173-178.
9	van Beers M, Janssen DJA, Gosker HR, et al. Cognitive impairment in chronic obstructive pulmonary disease: disease burden, determinants and possible future interventions[J]. Expert Rev Respir Med, 2018, 12(12): 1061-1074.
10	Turan O, Turan PA, Mirici A. Parameters affffecting inhalation therapy adherence in elderly patients with chronic obstructive lung disease and asthma[J]. Geriatr Gerontol Int, 2017, 17: 999-1005.
11	Yohannes Abebaw M, Eakin Michelle N, Holbrook Janet T, et al. Association of mild cognitive impairment and characteristic of COPD and overall health status in a cohort study[J]. Expert Rev Respir Med, 2021, 15: 153-159.
12	Xie Fei, Xie Lixin. COPD and the risk of mild cognitive impairment and dementia: a cohort study based on the Chinese Longitudinal Health Longevity Survey[J]. Int J Chron Obstruct Pulmon Dis, 2019, 14: 403-408.
13	Roberts RO, Knopman DS, Mielke MM, et al. Higher risk of progression to dementia in mild cognitive impairment cases who revert to normal[J]. Neurology, 2014, 82: 317-325.
14	Dag E, Bulcun E, Turkel Y, et al. Factors influencing cognitive function in subjects with COPD[J]. Respir Care, 2016, 61(8): 1044-11050.
15	郁芳芳，王　兰，刘澄英，等. 蒙特利尔认知评估量表在筛查慢阻肺患者轻度认知功能障碍的价值[J]. 临床肺科杂志，2018, 23(11): 113-115.
16	Dodd JW, Broek MVD. Cognitive loss in stable non-hypoxaemic patients with moderate chronic obstructive pulmonary disease[J] .Thorax，2010, 65(Suppl 4): A139-A140.
17	Chakraborty SI, Kaur S, Guha S, et al. The multifaceted roles of neutrophil gelatinase associated lipocalin (NGAL) in inflammation and cancer[J]. Biochim Biophys Acta, 2012, 1826(1): 129-169.
18	Bhusal Anup, Lee Won-Ha, Suk Kyoungho. Lipocalin-2 in diabetic complications of the nervous system: physiology, pathology, and beyond[J]. Front Physiol, 2021, 12: 638112.
19	Zhang Meng-Xia, Wang Li, Zheng Lei, et al. LCN2 Is a Potential biomarker for radioresistance and recurrence in nasopharyngeal carcinoma[J]. Front Oncol, 2020, 10: 605777.
20	Moschen AR, Adolph TE, Gerner RR, et al. Lipocalin-2: A Master Mediator of Intestinal and Metabolic Inflammation[J]. Trends Endocrinol Metab, 2017, 28(5): 388-397.
21	Abdallah Emad, Waked Emam, Al-Helal Bassam, et al. Novel troponin-like biomarkers of acute kidney injury[J]. Saudi J Kidney Dis Transpl, 2013, 24: 1111-1124.
22	Lippi G, Meschi T, Nouvenne A, et al. Neutrophil gelatinase-associated lipocalin in cancer[J]. Adv Clin Chem, 2014, 64: 179-219.
23	Nakai Michael E, Denham Joshua, Prestes Priscilla R, et al. Plasma lipocalin-2/NGAL is stable over 12 weeks and is not modulated by exercise or dieting[J]. Sci Rep, 2021, 11: 4056.
24	Dittrich AM, Meyer HA, Hamelmann E, et al. The role of lipocalins in airway disease[J] .Clin Exp Allergy, 2013, 43(5): 503-511.
25	Sevéus L, Amin K, Peterson CG, et al. Human neutrophil lipocalin (HNL) is a specific granule constituent of the neutrophil granulocyte. Studies in bronchial and lung parenchymal tissue and peripheral blood cells[J]. Histochem Cell Biol, 1997, 107(5): 423-432.

[1]	李大伟, 吴宏飞, 韩鹏, 孙盼盼, 邢红伟. 静脉-吸入复合麻醉与全静脉麻醉在老年腹腔镜疝修补术中应用效果比较[J]. 中华疝和腹壁外科杂志(电子版), 2023, 17(04): 458-462.
[2]	唐英俊, 李华娟, 王赛妮, 徐旺, 刘峰, 李羲, 郝新宝, 黄华萍. 人脐带间充质干细胞治疗COPD小鼠及机制分析[J]. 中华肺部疾病杂志(电子版), 2023, 16(04): 476-480.
[3]	徐丽玲, 卢玉宝, 赵彦, 任利, 李姝艺, 符娟, 康玲, 汪青松, 尤再春. COPD管理云平台的构建及临床应用[J]. 中华肺部疾病杂志(电子版), 2023, 16(04): 481-484.
[4]	李海明, 刘鸿飞, 李俊. 血清脂蛋白酶水平与COPD患者骨骼肌质量减少的关系[J]. 中华肺部疾病杂志(电子版), 2023, 16(04): 500-503.
[5]	周杉京, 诸葛金科, 王芳芳. 补肺活血胶囊对COPD患者cCor、ALD、Ang-Ⅱ的影响[J]. 中华肺部疾病杂志(电子版), 2023, 16(04): 517-519.
[6]	吴庆华, 冒勇, 闫效坤. AECOPD并发AKI的危险因素分析[J]. 中华肺部疾病杂志(电子版), 2023, 16(04): 529-531.
[7]	芦丹, 杨硕, 刘旭. VEGF、HMGB1、hs-CRP/Alb在AECOPD伴呼吸衰竭中的变化及预后分析[J]. 中华肺部疾病杂志(电子版), 2023, 16(04): 532-534.
[8]	熊锋, 娄建丽. 慢性阻塞性肺疾病急性加重期预后的临床分析[J]. 中华肺部疾病杂志(电子版), 2023, 16(04): 550-553.
[9]	王庆, 张红联, 吴志勇. COPD合并多重耐药菌肺部感染预后危险因素分析[J]. 中华肺部疾病杂志(电子版), 2023, 16(04): 557-559.
[10]	林静, 陈芳, 刘小霞. COPD患者认知功能障碍影响因素分析[J]. 中华肺部疾病杂志(电子版), 2023, 16(04): 569-571.
[11]	张七妹, 麦宜准, 蒋浩波. 喘可治对慢性阻塞性肺疾病缓解期的临床分析[J]. 中华肺部疾病杂志(电子版), 2023, 16(04): 578-580.
[12]	张林, 刘芳, 赵静, 刘勇, 周青. 远程康复在慢性阻塞性肺疾病患者肺康复中的研究进展[J]. 中华肺部疾病杂志(电子版), 2023, 16(04): 601-604.
[13]	吴新高, 李伟, 马俊, 刘红, 黄平. 癫痫患者定量脑电图功率谱相关参数与认知功能损伤的相关性研究[J]. 中华脑科疾病与康复杂志(电子版), 2023, 13(05): 304-308.
[14]	刘澳, 周菁, 孙永兵, 和俊雅, 林新贝, 乔琦, 李中林, 张建成, 武肖玲, 邹智, 胡扬喜, 肖新广, 吕雪, 李昊, 李永丽. 减重代谢手术后神经影像改变与认知功能评估的研究进展[J]. 中华肥胖与代谢病电子杂志, 2023, 09(03): 203-208.
[15]	刘感哲, 艾芬. MiRNA-210通过抑制HIF-1α的表达改善大鼠血管性认知功能障碍[J]. 中华脑血管病杂志(电子版), 2023, 17(05): 489-494.

阅读次数

全文

摘要

选择文件类型/文献管理软件名称

选择包含的内容

Expression and Significance of Serum lipocalin-2 in Patients with chronic obstructive pulmonary disease with Cognitive Impairment

模态框（Modal）标题

选择文件类型/文献管理软件名称

选择包含的内容

Expression and Significance of Serum lipocalin-2 in Patients with chronic obstructive pulmonary disease with Cognitive Impairment